Building a Patient Group for Non-Alcoholic Fatty Liver Disease and Creating Tests to Track Liver Fibrosis Progression

What this Trial Is About

Researchers are establishing a group of patients with non-alcoholic fatty liver disease NAFLD to develop markers that can predict how liver fibrosis progresses. The study focuses on collecting various clinical data and samples to better understand the changes in liver tissue and related health factors in these patients. Participants will undergo several evaluations including imaging tests like acoustic radiation force impulse elastography, supersonic shear wave elastography, and transient elastography to assess liver fibrosis. They will also have liver biopsies to analyze liver fat and fibrosis, with tissue samples stored for future research. Blood, serum, and other biological samples will be collected to study genetic and metabolic markers. Additional tests include body composition analysis, lung function tests, heart evaluations, brain imaging, endoscopy, colonoscopy, and sleep studies. During the study, patients will be regularly assessed using laboratory and radiologic methods. The main outcome measured is the grade of liver steatosis and fibrosis at baseline, with ongoing development of markers for fibrosis progression monitored every six months for up to one year. This involves detailed clinical, imaging, and laboratory evaluations to track disease changes over time.

Establishment of NAFLD Cohort and Development of Fibrosis Markers